Ignite Creation Date:
2024-05-06 @ 12:17 PM
Last Modification Date:
2024-10-26 @ 12:57 PM
Study NCT ID:
NCT03725059
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2023-12-18
First Post:
2018-10-29
Brief Title:
Study of Pembrolizumab MK-3475 Versus Placebo in Combination With Neoadjuvant Chemotherapy Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative ERHER2- Breast Cancer MK-3475-756KEYNOTE-756
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Key Dates - Follows AllAPIJSON File Order
Start Date:
2018-12-27
Start Date Type:
ACTUAL
Primary Completion Date:
2031-01-24
Primary Completion Date Type:
ESTIMATED
Completion Date:
2031-01-24
Completion Date Type:
ESTIMATED
First Submit Date:
2018-10-29
First Submit QC Date:
October 29 2018
Study First Post Date:
2018-10-30
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-12-12
Last Update Post Date:
2023-12-18
Last Update Post Date Type:
ACTUAL